7‑difluoromethoxyl‑5,4'‑di‑n‑octyl genistein inhibits ovarian cancer stem cell characteristics through the downregulation of FOXM1

Ning,Ying‑Xia; Li,Qing‑Xiu; Ren,Kai‑Qun; Quan,Mei‑Fang; Cao,Jian‑Guo

doi:10.3892/ol.2014.2080

7‑difluoromethoxyl‑5,4'‑di‑n‑octyl genistein inhibits ovarian cancer stem cell characteristics through the downregulation of FOXM1

Authors:
- Ying‑Xia Ning
- Qing‑Xiu Li
- Kai‑Qun Ren
- Mei‑Fang Quan
- Jian‑Guo Cao
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China, Laboratory of Medicine Engineering, Medical College, Hunan Normal University, Changsha, Hunan 410013, P.R. China
Published online on: April 22, 2014 https://doi.org/10.3892/ol.2014.2080
Pages: 295-300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

7‑Difluoromethoxyl‑5,4'‑di‑n‑octylgenistein (DFOG) is a novel synthetic genistein analogue that possesses anti‑cancer activity in a variety of cancers, including ovarian cancer. The objective of the present study was to investigate whether DFOG inhibits the self‑renewal capacity of ovarian cancer stem‑like cells (OCSLCs) and to identify its potential mechanism of action. It was found that the sphere‑forming cells (SFCs) of the SKOV3 cell line exhibited a self‑renewal capacity and high tumorigenicity, indicating that they possessed the properties of ovarian cancer stem cells (OCSCs). It was also shown for the first time that DFOG preferentially inhibited proliferation, self‑renewal capacity and expression of stem cell markers [cluster of differentiation (CD)133, CD44 and aldehyde dehydrogenase 1 (ALDH1)] in the SFCs derived from the SKOV3 cells. These effects were accompanied by the downregulation of forkhead box M1 (FOXM1) expression. Overexpression of FOXM1 rescued the DFOG‑induced downregulation of FOXM1, CD133, CD44 and ALDH1 protein expression. It also inhibited the self‑renewal capacity of the SFCs derived from the SKOV3 cells. Thus, DFOG appears to inhibit the characteristics of OCSLCs by downregulating FOXM1 expression.

View Figures

View References

1	Jelovac D and Armstrong DK: Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des. 18:3812–3815. 2012.
2	Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK and Wang SE: Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene. 30:1470–1480. 2011.
3	Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS and Arteaga CL: TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 123:1348–1358. 2013.
4	Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR and Cleary ML: Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 4:129–140. 2009.
5	Achilleos A and Trainor PA: Neural crest stem cells: discovery, properties and potential for therapy. Cell Res. 22:288–304. 2012.
6	Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL, Tang J, Chen WB and Zhang SN: Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int J Oncol. 41:1707–1714. 2012.
7	Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK and Ahmed N: Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 7:e468582012.
8	Ponnusamy MP, Seshacharyulu P, Vaz A, Dey P and Batra SK: MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J Ovarian Res. 4:72011.
9	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007.
10	Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 388:1257–1274. 2007.
11	Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H and Teh MT: Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 70:9515–9526. 2010.
12	Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH: Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem. 112:2296–2306. 2011.
13	Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:5592–5595. 1987.
14	Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD and Sarkar FH: Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther. 3:1271–1279. 2004.
15	Barnes S: Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 125(3 Suppl): 777S–783S. 1995.
16	Wang Z, Ahmad A, Banerjee S, Azmi A, Kong D, Li Y and Sarkar FH: FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res. 27:1159–1168. 2010.
17	Ning Y, Li Q, Xiang H, Liu F and Cao J: Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells. Oncol Rep. 27:1857–1864. 2012.
18	Xiang HL, Liu F, Quan MF, Cao JG and Lv Y: 7-difluoromethoxyl-5,4′-di-n-octylgenistein inhibits growth of gastric cancer cells through downregulating forkhead box M1. World J Gastroenterol. 18:4618–4626. 2012.
19	Reynolds BA and Weiss S: Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 175:1–13. 1996.
20	Shi X, Gipp J and Bushman W: Anchorage-independent culture maintains prostate stem cells. Dev Biol. 312:396–406. 2007.
21	Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008.
22	Van den Broeck A, Gremeaux L, Topal B and Vankelecom H: Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer. 12:3542012.
23	Penumatsa K, Edassery SL, Barua A, Bradaric MJ and Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res. 3:282010.
24	Creighton CJ, Chang JC and Rosen JM: Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 15:253–260. 2010.
25	Wang Z, Ahmad A, Li Y, Banerjee S, Kong D and Sarkar FH: Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 36:151–156. 2010.
26	Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 112:78–88. 2011.